ABBV vs MSFT: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-16.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Microsoft Corporation · Technology
$497.12
+41.3% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
MSFT has more upside to fair value
(+41.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MSFT |
| Current Price |
$261.70 |
$497.12 |
| Fair Value Estimate |
$259.04 |
$702.35 |
| Upside to Fair Value |
-1.0%
|
+41.3%
|
| Market Cap |
$462.4B |
$3,691.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
18.3x
|
| Price / Sales |
7.2x
|
11.1x
|
| Price / FCF |
23.6x
|
55.1x
|
| Revenue Growth YoY |
+10.2%
|
+17.7%
|
| Gross Margin |
71.5%
|
67.9%
|
| Operating Margin |
29.3%
|
46.8%
|
| Return on Equity |
-136.5%
|
33.2%
|
| Dividend Yield |
2.61% |
0.73% |
| FCF Yield |
4.25%
|
1.81%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings gr…
Accumulation Zones
| Metric |
ABBV |
MSFT |
| Zone Low |
$194.28 |
$526.76 |
| Zone High |
$220.18 |
$597.00 |
| In Buy Zone? |
No
|
Yes
|